NDAORALCAPSULE
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
EZALLOR SPRINKLE (rosuvastatin) by Fosun Pharma is hmg-coa reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme a to mevalonate, a precursor of cholesterol. Approved for hypercholesterolemia, dyslipidemia, hyperlipidemia. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EZALLOR SPRINKLE is an oral rosuvastatin capsule approved in 2018 that inhibits HMG-CoA reductase to lower cholesterol synthesis. It treats hypercholesterolemia, dyslipidemia, and multiple cardiovascular and metabolic conditions including coronary artery disease, acute coronary syndromes, and type 2 diabetes. The sprinkle formulation enables flexible dosing and administration for patients with swallowing difficulties.
$0.114BPart D
Peak9.8 years to LOEProduct is in peak lifecycle stage with modest Medicare spending; commercial team is likely stable but not rapidly expanding.
Mechanism of Action
HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.
Indications (3)
Worked on EZALLOR SPRINKLE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.